Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P.

Lancet. 1999 Jun 26;353(9171):2195-9. Erratum in: Lancet 1999 Sep 25;354(9184):1128.

PMID:
10392984
[PubMed - indexed for MEDLINE]
2.

Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.

Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P.

Antivir Ther. 2000 Mar;5(1):65-70.

PMID:
10846595
[PubMed - indexed for MEDLINE]
3.

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.

PMID:
10894268
[PubMed - indexed for MEDLINE]
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
5.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C.

HIV Med. 2004 Sep;5(5):352-9.

PMID:
15369510
[PubMed - indexed for MEDLINE]
6.

Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.

Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE.

AIDS Patient Care STDS. 2007 Aug;21(8):544-50.

PMID:
17711379
[PubMed - indexed for MEDLINE]
7.

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P.

AIDS. 2000 Jul 7;14(10):1333-9.

PMID:
10930147
[PubMed - indexed for MEDLINE]
8.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
[PubMed - indexed for MEDLINE]
9.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
[PubMed - indexed for MEDLINE]
10.

How does expert advice impact genotypic resistance testing in clinical practice?

Badri SM, Adeyemi OM, Max BE, Zagorski BM, Barker DE.

Clin Infect Dis. 2003 Sep 1;37(5):708-13. Epub 2003 Aug 15.

PMID:
12942405
[PubMed - indexed for MEDLINE]
Free Article
11.

An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.

Ormaasen V, Sandvik L, Asjø B, Holberg-Petersen M, Gaarder PI, Bruun JN.

HIV Med. 2004 Nov;5(6):400-6.

PMID:
15544691
[PubMed - indexed for MEDLINE]
12.

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group.

AIDS. 2002 Mar 29;16(5):727-36.

PMID:
11964529
[PubMed - indexed for MEDLINE]
13.

Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.

Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM.

AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):529-37.

PMID:
10777143
[PubMed - indexed for MEDLINE]
14.

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.

Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P.

HIV Med. 2004 Jul;5(4):284-8.

PMID:
15236618
[PubMed - indexed for MEDLINE]
15.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.

Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C.

AIDS. 2005 Oct 14;19(15):1643-7.

PMID:
16184034
[PubMed - indexed for MEDLINE]
16.

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.

Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.

J Med Virol. 1999 Dec;59(4):507-11.

PMID:
10534734
[PubMed - indexed for MEDLINE]
17.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
[PubMed - indexed for MEDLINE]
18.

Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.

Treichel S, Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procaccianti M, Klinker H, Petzoldt D.

Eur J Med Res. 2003 Sep 29;8(9):405-13.

PMID:
14555296
[PubMed - indexed for MEDLINE]
19.

[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.

PMID:
17457780
[PubMed - indexed for MEDLINE]
20.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

PMID:
11737402
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk